SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (44)9/6/2000 2:58:28 PM
From: aknahow   of 1022
 
How XOMA views it's HUMab technology. Not endorsing this view just posting for any that might be interested or for any that want to discuss it or diss it.


Human Engineering

What advantages does XOMA's Human Engineering technology have over
technologies such as transgenic mouse antibodies?
There are several distinct ways to prepare therapeutic antibodies with low
immunogenicity potential in humans. The XOMA Human Engineering technology
enables production of clinically useful antibodies from pre-existing mammalian
monoclonal antibodies, in contrast to transgenic mouse technology, which generates
antibodies de novo to existing targets. The effectiveness of any particular method of
generating an antibody with reduced immunogenicity will ultimately need to be
proved for each product in clinical trials. Nevertheless, advantages of XOMA's HE
method may include the following:

1. Simplicity. HE is a straightforward method for antibody modification
that can be directed by a computerized spreadsheet. This method can be
applied to ANY antibody sequence without additional experimentation.
2. Versatility. HE can improve the usefulness of the large number of
existing, well-characterized murine monoclonal antibodies to human
antigens that are already available. No new immunizations or selections are
required to create new "human" antibodies in mice for these already
identified targets.
3. Reliability. HE doesn't depend on the immune systems of transgenic
mice for the end product. Human Engineered™ antibodies retain the
binding characteristics of the 'parent' antibody
4. Speed: HE antibody genes can be generated in a few days. Mammalian
cell lines that express HE antibodies can be generated in approximately 3
months.
5. Economy: The HE method is easy to use, leading to potential cost
savings. There are no animals to maintain and only one royalty to pay.

If the XOMA HE technology is a novel approach why hasn't it been licensed
yet?
There is a large installed base of other licensed technology, and ours is a recent
entry. We are planning to initiate clinical studies in the next year with two HE
products, ING-1 and Genimune. These studies will provide data about how human
subjects respond to these compounds.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News